07:00 , Jul 15, 2013 |  BC Week In Review  |  Company News

Advancell, Helsinn deal

Advancell granted Helsinn exclusive, worldwide rights to develop and commercialize ATH008 . The undisclosed topical cream is in development to treat palmoplantar erythrodysesthesia syndrome (PPES) and hand-foot skin reactions (HFSR), which are painful cutaneous reactions...
07:00 , Apr 25, 2011 |  BC Week In Review  |  Clinical News

ATH008: Phase IIb started

Advancell began a double-blind, placebo-controlled, European Phase IIb trial to evaluate twice-daily 1%, 3% and 8% ATH008 in up to 100 patients with PPES secondary to capecitabine monotherapy. Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) markets capecitabine...